Key result
Hyperkalemia at admission significantly increased median hospitalization days from 7.4 to 12.1 days compared to non-hyperkalemia in patients with advanced chronic kidney disease and type 2 diabetes.
Why the study?
The study aimed to explore the impact of hyperkalemia at admission on hospitalization days among patients with advanced chronic kidney disease and type 2 diabetes mellitus in China.
Does hyperkalemia at admission increase hospitalization days in advanced CKD patients with T2DM?
Cohort (n=270)
No
Does hyperkalemia at admission increase hospitalization days in advanced CKD patients with T2DM?
Absolute Event Rate: 12.1% vs 7.4%
p-value: p=<0.001
Hyperkalemia at admission is an independent risk factor for prolonged hospitalization in patients with advanced chronic kidney disease and type 2 diabetes.
Hyperkalemia at admission was associated with longer stays in advanced CKD with T2DM; leaves open whether early correction shortens hospitalization.
Objective: This study aimed to explore the impact of hyperkalemia at admission on hospitalization days (HDs) among advanced chronic kidney disease patients (CKD) with type two diabetes mellitus (T2DM) in China. Methods: A total of 270 CKD patients with T2DM were prospectively selected from January 1, 2020 to December 31, 2021. These patients were divided into Group-A (n = 150, serum potassium ≤ 5.5 mmol/L) and B (n = 120, serum potassium > 5.5 mmol/L). The comparison method between the two groups was taken. Linear correlation analysis was performed using the Spearman correlation method, and multivariate analysis was tested using linear regression. Results: The study found statistically significant result between the two groups (Group-A vs Group-B): HDs (7.4 (5.3-11.2) vs 12.1 (8.2-16.5), p < 0.001), renin-angiotensin-aldosterone system inhibitors (RAASIs) (36.2% vs 55.8%, p = 0.014), systolic blood pressure (148.35 ± 19.51 vs 162.26 ± 21.31, p < 0.05), estimated glomerular filtration (eGFR) (20.35) (18.31-25.26) vs13.4 (12.50-18.50), p < 0.001, N-terminal pro-B type natriuretic peptide (NT-proBNP) (2245.42 ± 61.09 vs 3163.39 ± 85.15,p < 0.001), and Hb (88.45 ± 12.35 vs 72.26 ± 14.2, p = 0.023). Correlation analysis showed that HDs were positively correlated with age, serum potassium, systolic blood pressure, and NT-proBNP, while negatively with eGFR and Hb. After adjusting for relevant confounding variables, the multivariable linear regression analysis showed that hyperkalemia was an independent risk factor for HDs. Conclusions: Hyperkalemia could be an independent risk factor increasing HDs of advanced CKD patients with T2DM. doi: https://doi.org/10.12669/pjms.39.3.6874 How to cite this: Li X, Li X, Li B, Guo Y. Impact of hyperkalemia on hospitalization days in advanced chronic kidney disease patients with Type-2 diabetes mellitus: A prospective study. Pak J Med Sci. 2023;39(3):885-890. doi: https://doi.org/10.12669/pjms.39.3.6874 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) conducted a cohort in Advanced chronic kidney disease with Type-2 diabetes mellitus (n=270). Hyperkalemia (serum potassium > 5.5 mmol/L) vs. Non-hyperkalemia (serum potassium ≤ 5.5 mmol/L) was evaluated on Hospitalization days (HDs) (p=<0.001). Hyperkalemia at admission significantly increased median hospitalization days from 7.4 to 12.1 days compared to non-hyperkalemia in patients with advanced chronic kidney disease and type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: